We are a biotech company solving some of the world's most significant healthcare problems, so that people and animals around the world are free to live their best life.

Learn More

Mountain Valley MD - "Infinite Possibility"

Infinite Possibility.

Mountain Valley MD News

Stay up to date on all Mountain Valley MD News and Videos.

Subscribe To Updates

MVMD CEO insight on Monderna inclusion in S&P Index

Article

July 21, 2021

MVMD CEO insight on Monderna inclusion in S&P Index

Watch Video

Read Article View Image

Article

July 14, 2021

This Entrepreneur Is On A Mission To Tackle Global Health Challenges

Watch Video

Read Update Read Article Read Press Release View Image

Article

July 21, 2021

MVMD CEO insight on Monderna inclusion in S&P Index

Watch Video

Read Update Read Article Read Press Release View Image

Article

July 21, 2021

Dennis Hancock of Mountain Valley MD: In Light Of The Pandemic, Here Are The 5 Things We Need To Do To Improve The US Healthcare System

Watch Video

Read Update Read Article Read Press Release View Image

Video

July 15, 2021

MVMD CEO discusses strategy behind new advisor additions.

Watch Video

Read Update Read Article Read Press Release View Image

Article

July 12, 2021

Mountain Valley MD Pursues Ambitious Initiatives, Including Partnership With FDA

Watch Video

Read Update Read Article Read Press Release View Image

Video

July 9, 2021

MVMD Interview on Cold Chain Results & Broad Corporate Update

Watch Video

Read Update Read Article Read Press Release View Image

CEO Update

July 7, 2021

CEO Update: MVMD Announces Results from FDA Cold Chain Evaluation

Watch Video

Read Update Read Article Read Press Release View Image

Article

June 25, 2021

Emerging Biotech Company MVMD Looks To Take On Cancer, COVID-19 And More

Watch Video

Read Update Read Article Read Press Release View Image

Article

June 25, 2021

A Promising COVID-19 Treatment May Succeed Where Vaccines Can't Reach

Watch Video

Read Update Read Article Read Press Release View Image

Video

June 21, 2021

MVMD Shareholder “Ask Me Anything” Interview Continued - Part 2

Watch Video

Read Update Read Article Read Press Release View Image

Video

June 17, 2021

MVMD Shareholder “Ask Me Anything” Interview Continued - Part 1

Watch Video

Read Update Read Article Read Press Release View Image

Article

June 17, 2021

Solubilised ivermectin improves drug delivery

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 28, 2021

The Only Reason You Might Not Need a COVID Booster Shot, Doctors Say

Watch Video

Read Update Read Article Read Press Release View Image

Video

May 27, 2021

Mountain Valley MD Town Hall AMA - May 26th, 2021

Watch Video

Read Update Read Article Read Press Release View Image

Video

May 19, 2021

MVMD CEO Dennis Hancock Talks Ivectosol Results, The Politicization Of Ivermectin, And More

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 18, 2021

MVMD Coverage by Industry Wired - 10 US Pharma Stocks To Buy & Hold During COVID-19

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 18, 2021

MVMD Coverage by BioWorld™

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 18, 2021

CANCER INNOVATION – MOUNTAIN VALLEY MD

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 14, 2021

MVMD Coverage by ZeroHedge

Watch Video

Read Update Read Article Read Press Release View Image

Video

May 7, 2021

MVMD’s CEO interviewed on the Dahlia Kurtz Show

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 6, 2021

Mountain Valley MD CEO thinks investors should be excited about the company’s ability to bring technology into commercialization this year

Watch Video

Read Update Read Article Read Press Release View Image

Video

May 5, 2021

Mountain Valley MD ( MVMD:CSE ) Proceeding With Pre-Clinical Cancer Trials & Files Related Patent

Watch Video

Read Update Read Article Read Press Release View Image

Video

May 4, 2021

Mountain Valley MD preparing to start pre-clinical trial for use of ivermectin to target cancer

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 4, 2021

Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 4, 2021

Mountain Valley MD files patent and begins pre-clinical trials to enter USD $100 billion cancer drug market

Watch Video

Read Update Read Article Read Press Release View Image

Article

May 2, 2021

Covid crisis: Should India be a warning for other countries? MVMD Weighs In.

Watch Video

Read Update Read Article Read Press Release View Image

Video

April 27, 2021

MVMD’s CEO interviewed on the Shaun Proulx Show.

Watch Video

Read Update Read Article Read Press Release View Image

Video

April 22, 2021

Mountain Valley MD (MVMD.C) CEO, Dennis Hancock's & Ivermectin trials update (Ep 50) FG/JV

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 20, 2021

Q&A With Mountain Valley MD's CEO & President, Dennis Hancock

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 18, 2021

This Small Company Has Plans to Change the World! Mountain Valley MD Holdings | MVMDF | MVMD

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 18, 2021

Mountain Valley MD (MVMD.C) president and CEO, Dennis Hancock's latest update (Ep 39) FG/JV

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 16, 2021

Mountain Valley about to start animal trials in Bangladesh while also beginning production pipeline

Watch Video

Read Update Read Article Read Press Release View Image

Press Release

March 10, 2021

Mountain Valley MD Achieves Solubilization of Selamectin, Files Trademark for Selactosol™

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 10, 2021

Mountain Valley MD takes major step forward achieving Solubilization of Selamectin

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 3, 2021

Mountain Valley MD FDA Application 1st Step Toward Human Applications For Game Changing Ivectosol™

Watch Video

Read Update Read Article Read Press Release View Image

Video

March 3, 2021

Mountain Valley MD proceeding with program to get FDA approval for Novel Ivectosol

Watch Video

Read Update Read Article Read Press Release View Image

Article

March 1, 2021

Mountain Valley MD Holdings poised for animal trials on its Ivectosol 1% solution

Watch Video

Read Update Read Article Read Press Release View Image

Video

February 25, 2021

Kevin O'Leary AKA Mr. Wonderful Shares His Thoughts on MVMD!

Watch Video

Read Update Read Article Read Press Release View Image

Video

February 22, 2021

First Glance with Jody Vance (E26): Update from Mountain Valley MD (MVMD. C) management team

Watch Video

Read Update Read Article Read Press Release View Image

Video

February 22, 2021

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

Watch Video

Read Update Read Article Read Press Release View Image

Article

February 18, 2021

GTA company working on the treatment side of Covid

Watch Video

Read Update Read Article Read Press Release View Image

Article

February 15, 2021

Mountain Valley MD Broadens U.S. Investor Outreach With OTC Listing Beginning February 16

Watch Video

Read Update Read Article Read Press Release View Image

Article

February 11, 2021

Ivermectin: Major tech breakthrough in human application, as scientists aim to save world from Covid-19 and malaria

Watch Video

Read Update Read Article Read Press Release View Image

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“This is the best interview Agoracom has done in the last ten years. If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.”

- George Tsiolis, President of Agoracom

“Embedding Mountain Valley MD’s Quicksome™️ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace... The initial consumer testing with our energy and sleep products has been very well received. The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”

- Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and Founder of Peak Human Labs.

“This breakthrough is a major game-changer for the future potential administration of Ivermectin, and perhaps other drug and vaccine applications. Applied to Ivermectin, Mountain Valley’s Quicksome technology greatly improved its therapeutic potential.”

- Benjamin Smith, The Dales Report

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“MVMD has developed a tablet that dissolves easily, with a fraction of the dose, of wonder drug Ivermectin.”

- Jackie Cameron, BizNews

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD’s Quicksol™ technology.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“MVMD takes existing vaccines and drugs – and delivers them better. Both into the body and by transportation to the world. Way better.”

- George Tsiolis, President of Agoracom

“MVMD’s technology showed greater pharmacokinetic performance, more rapid onset times, with greater drug distribution and stability in the canines trialled—at 1/5 the dosages compared to existing oral and subcutaneous injection solutions.”

- Benjamin Smith, The Dales Report

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments.”

Recent News

MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS, STOCK OPTION GRANT AND PROVIDES UPLISTING UPDATE

MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS, STOCK OPTION GRANT AND PROVIDES UPLISTING UPDATE

MOUNTAIN VALLEY MD ANNOUNCES RESULTS FROM COLD CHAIN STORAGE EVALUATION OF NOVEL QUICKSOME™ TECHNOLOGY

MOUNTAIN VALLEY MD ANNOUNCES RESULTS FROM COLD CHAIN STORAGE EVALUATION OF NOVEL QUICKSOME™ TECHNOLOGY

MOUNTAIN VALLEY MD PROVIDES UPDATE ON KEY STRATEGIC INITIATIVES: PATENT AWARD, FDA COLLABORATIVE RESEARCH AGREEMENT, COLD CHAIN, DOSE SPARING, HUSBANDRY, ONCOLOGY, TB, CANNABIS

MOUNTAIN VALLEY MD PROVIDES UPDATE ON KEY STRATEGIC INITIATIVES: PATENT AWARD, FDA COLLABORATIVE RESEARCH AGREEMENT, COLD CHAIN, DOSE SPARING, HUSBANDRY, ONCOLOGY, TB, CANNABIS

MOUNTAIN VALLEY MD TO HOST LIVE, VIRTUAL TOWN HALL Q&A SESSION WITH COMPANY PRESIDENT & CEO, DENNIS HANCOCK

MOUNTAIN VALLEY MD TO HOST LIVE, VIRTUAL TOWN HALL Q&A SESSION WITH COMPANY PRESIDENT & CEO, DENNIS HANCOCK

MOUNTAIN VALLEY MD RECEIVES SUCCESSFUL RESULTS FROM BSL-4 COVID-19 CLEARANCE TRIAL ON THREE VARIANTS TESTED WITH IVECTOSOL™

MOUNTAIN VALLEY MD RECEIVES SUCCESSFUL RESULTS FROM BSL-4 COVID-19 CLEARANCE TRIAL ON THREE VARIANTS TESTED WITH IVECTOSOL™

MOUNTAIN VALLEY MD PROVIDES UPDATE ON CURRENT TRIALS

MOUNTAIN VALLEY MD PROVIDES UPDATE ON CURRENT TRIALS

MOUNTAIN VALLEY MD PROCEEDING WITH PRE-CLINICAL CANCER TRIALS, FILES RELATED CANCER PATENT

MOUNTAIN VALLEY MD PROCEEDING WITH PRE-CLINICAL CANCER TRIALS, FILES RELATED CANCER PATENT

MOUNTAIN VALLEY MD HOLDINGS INC. PROCEEDING WITH APPLICATION TO LIST ON THE TSX VENTURE EXCHANGE

MOUNTAIN VALLEY MD HOLDINGS INC. PROCEEDING WITH APPLICATION TO LIST ON THE TSX VENTURE EXCHANGE

MOUNTAIN VALLEY MD COMMENCING TRIALS IN BANGLADESH, STRIKING PHARMACEUTICAL PRODUCTION AGREEMENTS

MOUNTAIN VALLEY MD COMMENCING TRIALS IN BANGLADESH, STRIKING PHARMACEUTICAL PRODUCTION AGREEMENTS

MOUNTAIN VALLEY MD ACHIEVES SOLUBILIZATION OF SELAMECTIN, FILES TRADEMARK FOR SELACTOSOL™

MOUNTAIN VALLEY MD ACHIEVES SOLUBILIZATION OF SELAMECTIN, FILES TRADEMARK FOR SELACTOSOL™

MOUNTAIN VALLEY MD PROCEEDING WITH FDA 505(b)(2) PATHWAY APPLICATION FOR NOVEL IVECTOSOL™

MOUNTAIN VALLEY MD PROCEEDING WITH FDA 505(b)(2) PATHWAY APPLICATION FOR NOVEL IVECTOSOL™

MOUNTAIN VALLEY MD COMMENCING HUSBANDRY ANIMAL TRIALS, APPOINTS SEASONED DOCTOR OF VETERINARY MEDICINE TO ADVISORY BOARD

MOUNTAIN VALLEY MD COMMENCING HUSBANDRY ANIMAL TRIALS, APPOINTS SEASONED DOCTOR OF VETERINARY MEDICINE TO ADVISORY BOARD

MOUNTAIN VALLEY MD CONFIRMS QUICKSOME™ LICENSE AGREEMENT, FIRST REVENUES

MOUNTAIN VALLEY MD CONFIRMS QUICKSOME™ LICENSE AGREEMENT, FIRST REVENUES

MOUNTAIN VALLEY MD TO INCLUDE TESTING OF SOUTH AFRICAN MUTATION IN UPCOMING COVID-19 BSL-4 CLEARANCE WORK

MOUNTAIN VALLEY MD TO INCLUDE TESTING OF SOUTH AFRICAN MUTATION IN UPCOMING COVID-19 BSL-4 CLEARANCE WORK

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STOCK OPTION GRANT AND WARRANT EXERCISE UPDATE

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STOCK OPTION GRANT AND WARRANT EXERCISE UPDATE

MOUNTAIN VALLEY MD HOLDINGS TO COMMENCE TRADING ON OTCQB MARKET UNDER TICKER MVMDF

MOUNTAIN VALLEY MD HOLDINGS TO COMMENCE TRADING ON OTCQB MARKET UNDER TICKER MVMDF

MOUNTAIN VALLEY MD CONTRACTS TULANE UNIVERSITY FOR ADJUVANT IPV STUDY

MOUNTAIN VALLEY MD CONTRACTS TULANE UNIVERSITY FOR ADJUVANT IPV STUDY

MOUNTAIN VALLEY MD PROCEEDING WITH COVID-19 CLEARANCE TRIAL IN LEVEL 4 BIOHAZARD FACILITY

MOUNTAIN VALLEY MD PROCEEDING WITH COVID-19 CLEARANCE TRIAL IN LEVEL 4 BIOHAZARD FACILITY

MOUNTAIN VALLEY MD FILES PATENT FOR NOVEL VACCINE DOSE SPARING ADJUVANT

MOUNTAIN VALLEY MD FILES PATENT FOR NOVEL VACCINE DOSE SPARING ADJUVANT

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

MOUNTAIN VALLEY MD SECURES QUICKSOME™ LICENSE AGREEMENT AND STRATEGIC SALE OF SUBSIDIARY

MOUNTAIN VALLEY MD SECURES QUICKSOME™ LICENSE AGREEMENT AND STRATEGIC SALE OF SUBSIDIARY

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES INTELLECTUAL PROPERTY ASSET TRANSFER, SOLIDIFIES QUICKSOME TECHNOLOGY

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES INTELLECTUAL PROPERTY ASSET TRANSFER, SOLIDIFIES QUICKSOME TECHNOLOGY

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES NEW CFO, NEW BOARD MEMBER AND TRANSITION OF PREVIOUS CFO TO ADVISORY ROLE

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES NEW CFO, NEW BOARD MEMBER AND TRANSITION OF PREVIOUS CFO TO ADVISORY ROLE

MOUNTAIN VALLEY MD HOLDINGS INC. PROVIDES UPDATE ON INTELLECTUAL PROPERTY ASSETS, COMPLETES SHARES FOR DEBT TRANSACTION AND GRANT OF OPTIONS

MOUNTAIN VALLEY MD HOLDINGS INC. PROVIDES UPDATE ON INTELLECTUAL PROPERTY ASSETS, COMPLETES SHARES FOR DEBT TRANSACTION AND GRANT OF OPTIONS

MOUNTAIN VALLEY MD HOLDINGS INC. COMMENCES TRADING ON CSE UNDER TICKER “MVMD”

MOUNTAIN VALLEY MD HOLDINGS INC. COMMENCES TRADING ON CSE UNDER TICKER “MVMD”

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES APPROVAL OF CSE LISTING

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES APPROVAL OF CSE LISTING

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES REVERSE TAKEOVER TRANSACTION